Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its earnings results on Thursday. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01, Briefing.com reports. The business had revenue of $75.54 million for the quarter, compared to analysts’ expectations of $76.84 million. Amphastar Pharmaceuticals had a positive return on equity of 2.15% and a negative net margin of 3.39%. The business’s revenue for the quarter was up 30.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.07 EPS.
NASDAQ AMPH traded up $0.88 during midday trading on Friday, hitting $21.59. 735,306 shares of the company traded hands, compared to its average volume of 117,925. Amphastar Pharmaceuticals has a 52 week low of $14.40 and a 52 week high of $21.65. The company has a current ratio of 1.94, a quick ratio of 1.24 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $890.44 million, a PE ratio of 56.82, a price-to-earnings-growth ratio of 8.77 and a beta of 1.38.
Several brokerages have issued reports on AMPH. BidaskClub cut Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 13th. Needham & Company LLC dropped their target price on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 10th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Friday. ValuEngine raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 17th. Finally, Zacks Investment Research raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Amphastar Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $23.00.
In other news, CFO William J. Peters sold 2,407 shares of the stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $17.59, for a total transaction of $42,339.13. Following the completion of the sale, the chief financial officer now owns 86,836 shares in the company, valued at approximately $1,527,445.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of the stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $17.82, for a total value of $178,200.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,502 shares of company stock valued at $558,373. Company insiders own 31.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/11/10/amphastar-pharmaceuticals-amph-announces-quarterly-earnings-results.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.